In the last trading session, 1.33 million Seres Therapeutics Inc (NASDAQ:MCRB) shares changed hands as the company’s beta touched 2.52. With the company’s per share price at $0.75 changed hands at $0.01 or 1.19% during last session, the market valuation stood at $130.19M. MCRB’s last price was a discount, traded about -104.0% off its 52-week high of $1.53. The share price had its 52-week low at $0.54, which suggests the last value was 28.0% up since then. When we look at Seres Therapeutics Inc’s average trading volume, we note the 10-day average is 0.81 million shares, with the 3-month average coming to 1.47 million.
Analysts gave the Seres Therapeutics Inc (MCRB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.67. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MCRB as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Seres Therapeutics Inc’s EPS for the current quarter is expected to be 0.08.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Instantly MCRB was in green as seen at the end of in last trading. With action 3.94%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -10.14%, with the 5-day performance at 3.94% in the green. However, in the 30-day time frame, Seres Therapeutics Inc (NASDAQ:MCRB) is -10.33% down. Looking at the short shares, we see there were 17.23 million shares sold at short interest cover period of 22.25 days.
The consensus price target for the stock as assigned by Wall Street analysts is 1.25, meaning bulls need an upside of 40.0% from its current market value. According to analyst projections, MCRB’s forecast low is 1.25 with 1.25 as the target high. To hit the forecast high, the stock’s price needs a -66.67% plunge from its current level, while the stock would need to soar -66.67% for it to hit the projected low.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 16.67M. 6 analysts are of the opinion that Seres Therapeutics Inc’s revenue for the current quarter will be 4.17M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 5.34%.
MCRB Dividends
Seres Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.02% of Seres Therapeutics Inc shares while 36.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 41.60%. There are 36.18% institutions holding the Seres Therapeutics Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 15.5489% of the shares, roughly 22.72 million MCRB shares worth $16.44 million.
FLAGSHIP PIONEERING INC. holds the second largest percentage of outstanding shares, with 15.2573% or 23.12 million shares worth $16.73 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . With 6.81 shares estimated at $5.08 million under it, the former controlled 3.90% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.21% of the shares, roughly 3.86 shares worth around $2.88 million.
